ロード中...
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, nota...
保存先:
| 出版年: | Clin Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5848255/ https://ncbi.nlm.nih.gov/pubmed/30060024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix523 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|